University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Fernando Velayos, M.D.

Gastroenterologist

Clinics

Gastroenterology at Mount Zion
1701 Divisadero St., Suite 120
San Francisco, CA 94115
Phone: (415) 502-4444
Fax: (415) 502-2249

Hours: Monday to Friday
9 a.m. – 4:30 p.m.

Inflammatory Bowel Disease Center
1701 Divisadero St., Suite 120
San Francisco, CA 94115
Phone: (415) 502-4444
Fax: (415) 502-2249

More about Fernando Velayos

Education

UCSF School of Medicine 1997

Residencies

UCSF Medical Center, Internal Medicine 2001

Fellowships

UCSF Medical Center 2004

Selected Research and Publications

  1. Day LW, Velayos F. Colorectal Cancer of the Elderly. Curr Treat Options Gastroenterol. 2014 Jun 18.
  2. Nett A, Velayos F, McQuaid K. Quality bowel preparation for surveillance colonoscopy in patients with inflammatory bowel disease is a must. Gastrointest Endosc Clin N Am. 2014 Jul; 24(3):379-92.
  3. Day LW, Velayos F. Colorectal cancer and the elderly. Clin Geriatr Med. 2014 Feb; 30(1):117-31.
  4. Long MD, Hutfless S, Kappelman MD, Khalili H, Kaplan GG, Bernstein CN, Colombel JF, Gower-Rousseau C, Herrinton L, Velayos F, Loftus EV, Nguyen GC, Ananthakrishnan AN, Sonnenberg A, Chan A, Sandler RS, Atreja A, Shah SA, Rothman KJ, Leleiko NS, Bright R, Boffetta P, Myers KD, Sands BE. Challenges in designing a national surveillance program for inflammatory bowel disease in the United States. Inflamm Bowel Dis. 2014 Feb; 20(2):398-415.
  5. Hwang C, Velayos F. On the Question of Ethnicity and Its Impact on IBD-Related Outcomes. Dig Dis Sci. 2014 Jan; 59(1):19-21.
  6. Velayos F. Reply. Clin Gastroenterol Hepatol. 2014 Feb; 12(2):346.
  7. Li D, Collins B, Velayos FS, Liu L, Lewis JD, Allison JE, Flowers NT, Hutfless S, Abramson O, Herrinton LJ. Racial and ethnic differences in health care utilization and outcomes among ulcerative colitis patients in an integrated health-care organization. Dig Dis Sci. 2014 Feb; 59(2):287-94.
  8. Siao D, Velayos F. Avoiding rash decision making: skin cancer screening of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014 Feb; 12(2):274-6.
  9. Truta B, Li DX, Mahadevan U, Fisher ER, Chen YY, Grace K, Velayos F, Terdiman JP. Serologic markers associated with development of Crohn's disease after ileal pouch anal anastomosis for ulcerative colitis. Dig Dis Sci. 2014 Jan; 59(1):135-45.
  10. Velayos FS, Ullman TA. Looking forward to understanding and reducing colorectal cancer risk in inflammatory bowel disease. Gastroenterology. 2013 Jul; 145(1):47-9.
  11. Sewell JL, Velayos FS. Systematic review: The role of race and socioeconomic factors on IBD healthcare delivery and effectiveness. Inflamm Bowel Dis. 2013 Mar; 19(3):627-43.
  12. Velayos FS, Kahn JG, Sandborn WJ, Feagan BG. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol. 2013 Jun; 11(6):654-66.
  13. Akbari M, Shah S, Velayos FS, Mahadevan U, Cheifetz AS. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013 Jan; 19(1):15-22.
  14. Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD, Velayos F. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology. 2012 Aug; 143(2):382-9.
  15. Sai VF, Velayos F, Neuhaus J, Westphalen AC. Colonoscopy after CT diagnosis of diverticulitis to exclude colon cancer: a systematic literature review. Radiology. 2012 May; 263(2):383-90.
  16. Velayos F. Managing risks of neoplasia in inflammatory bowel disease. Curr Gastroenterol Rep. 2012 Apr; 14(2):174-80.
  17. Cheifetz AS, Melmed GY, Spiegel B, Talley J, Devlin SM, Raffals L, Irving PM, Jones J, Kaplan GG, Kozuch P, Sparrow M, Velayos F, Baidoo L, Bressler B, Siegel CA. Setting priorities for comparative effectiveness research in inflammatory bowel disease: results of an international provider survey, expert RAND panel, and patient focus groups. Inflamm Bowel Dis. 2012 Dec; 18(12):2294-300.
  18. Lin KK, Velayos F, Fisher E, Terdiman JP. Durability of infliximab dose intensification in Crohn's disease. Dig Dis Sci. 2012 Apr; 57(4):1013-9.
  19. Day LW, Walter LC, Velayos F. Colorectal cancer screening and surveillance in the elderly patient. Am J Gastroenterol. 2011 Jul; 106(7):1197-206;quiz 1207.
  20. Siao D, Velayos FS. The good, the bad, and the ugly: adverse events and Crohn's therapies. Inflamm Bowel Dis. 2010 Aug; 16(8):1443-4.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.